期刊
JOURNAL OF HEMATOLOGY & ONCOLOGY
卷 11, 期 -, 页码 -出版社
BIOMED CENTRAL LTD
DOI: 10.1186/s13045-017-0551-7
关键词
Pancreatic ductal adenocarcinoma; Novel regimens; Biomarkers; Combination therapies
资金
- National Natural Science Foundation of China [81370065, 81372653]
- basic research project of the Science and Technology Commission of Shanghai Municipality [15JC1401200]
- National Science Fund for Distinguished Young Scholars [81625016]
A poor prognosis of pancreatic ductal adenocarcinoma (PDAC) associated with chemoresistance has not changed for the past three decades. A multidisciplinary diagnosis followed by surgery and chemo(radiation) therapy is the main treatment approach. However, gemcitabine-and 5-fluorouracil-based therapies did not present satisfying outcomes. Novel regimens targeting pancreatic cancer cells, the tumor microenvironment, and immunosuppression are emerging. Biomarkers concerning the treatment outcome and patient selection are being discovered in preclinical or clinical studies. Combination therapies of classic chemotherapeutic drugs and novel agents or novel therapeutic combinations might bring hope to the dismal prognosis for PDAC patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据